Immediate Impact

1 by Nobel laureates 4 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Covalent targeted radioligands potentiate radionuclide therapy
2024 StandoutNature
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
10 intermediate papers

Works of Michael Stabin being referenced

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
2000
Samarium-153-EDTMP biodistribution and dosimetry estimation.
1993
and 1 more

Author Peers

Author Last Decade Papers Cites
Michael Stabin 409 176 26 145 15 558
M.T. Hays 426 148 9 85 13 607
Woutjan Branderhorst 439 230 7 109 17 647
Phillips Tl 135 143 8 95 22 462
D.F. Sacker 359 155 23 110 20 595
Alexander Bruskin 350 60 50 144 31 542
Glenda Y. Ross 232 192 12 96 21 474
Gould A. Andrews 239 146 15 70 30 565
Jan Wondergem 260 102 6 80 17 562
Gregor J. Förster 265 104 6 81 18 472
Galina Iosilevsky 270 138 5 101 26 534

All Works

Loading papers...

Rankless by CCL
2026